Ansun Biopharma, Inc.
Records under this name other than the patents Ansun Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Showing 1 to 9 of 9 · Back to Ansun Biopharma, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,807,174 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Feb 9, 2026 · High confidence | Term ended | Term ended Feb 9, 2026 | High confidence |
| US 11,241,486 | Treatment of Middle East respiratory syndrome coronavirus Lapsed on the fee record Ended Feb 8, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 8, 2026 | USPTO record |
| US 7,645,448 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · High confidence | Term ended | Term ended Sep 10, 2024 | High confidence |
| US 8,512,710 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 8,722,869 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 9,212,353 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 9,764,007 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 10,525,109 | Novel Class of Therapeutic Protein Based Molecules Term ended Term ended Sep 10, 2024 · Medium confidence | Term ended | Term ended Sep 10, 2024 | Medium confidence |
| US 8,084,036 | Broad spectrum anti-viral therapeutics and prophylaxis Term ended Term ended Jun 21, 2024 · USPTO record | Term ended | Term ended Jun 21, 2024 | USPTO record |